Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
VALBY, Denmark, 15 September, 2026 // -- H. Lundbeck A/S (Lundbeck) today announced that the last patient has been randomized in DEEp SEA (NCT06660394), a global Phase III clinical trial evaluating the efficacy, safety and tolerability of bexicaserin for the treatment of seizures in child…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.